Industry and Advocacy Groups Urge FDA to Allow More Real-World Data for Rare Disease Trials

[cafead]

via In January 2019, the U.S. Food and Drug Administration (FDA) updated a 2015 draft guidance on rare diseases. Although essentially agreeing with the changes, several organizations, both patient advocacy and industry groups, have called on the FDA to make additional changes.

article source